Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.4.1 (phosphodiesterase)
18,767 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of cyclic AMP and related compounds on both in vivo and in vitro epidermal cell migration during wound closure in the adult newt was examined. Cyclic AMP (cAMP) and N6,O2'-dibutyryl cyclic AMP (db-cAMP) inhibited migration both in vivo and in vitro when used with equimolar concentrations of theophylline, an inhibitor of 3',5'-cyclic nucleotide phosphodiesterase. Neither db-cAMP nor theophylline alone inhibited migration in vivo. Adenosine 5' monophosphate (AMP), cyclic guanosine 3',5' monophosphate (cGMP) and imidazole, a potentiator of phosphodiesterase were tested in vivo and had no effect on migration. Isoproterenol and epinephrine, which are known to stimulate adenylate cyclase, inhibited migration in vitro. Experiments using the protein synthesis inhibitor, cycloheximide, suggest that cAMP could be acting partially through regulation of protein synthesis but that other factors are involved. Dibutyryl cyclic AMP and theophylline had no effect on the incorporation of 3H-leucine into protein. The inhibition of migration both in vivo and in vitro provides further evidence for a role of cAMP in the regulation of cell motility.
...
PMID:Effect of cAMP and related compounds on newt epidermal cell migration both in vivo and in vitro. 625 Nov 54

Isolated human granulocytes secrete the lysosomal enzyme beta glucuronidase when incubated with complement-activated zymosan particles. Isoproterenol inhibits this release, and the beta adrenergic response is associated with an increase in granulocyte cyclic adenosine monophosphate (cAMP) levels. In asthma, the beta adrenergic responsiveness is impaired. Cyclic AMP concentration in the granulocyte is also influenced by phosphodiesterase hydrolysis of this cyclic nucleotide. We found that the potent phosphodiesterase inhibitor, RO 20-1724, inhibited zymosan-stimulated beta glucuronidase release from granulocytes in a dose-dependent fashion (10(-8) to 10(-4) M). The inhibition of lysosomal enzyme release by RO 20-1724 was associated with an increase in granulocyte cAMP. Granulocytes were also isolated from asthmatic patients and the RO 20-1724 inhibition of beta glucuronidase release was compared with the response in normal subjects. The negative log molar median effective dose (ED50) value (mean +/- SE) was 5.98 +/- 0.69 in normal subjects and 5.90 +/- 0.63 in asthmatics. These observations suggest that the granulocyte metabolism modulated by the RO 20-1724-sensitive phosphodiesterase is equally responsive to this potent phosphodiesterase inhibitor in normal and asthmatic leukocytes.
...
PMID:The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthma. 625 24

Renal prostaglandins (PGs) have been considered to be important mediators of renin release. However, the mechanism and the site of action have not been clarified. To investigate the role of PGs in the control of isoproterenol-induced renin release, we studied the effect of two inhibitors of PG synthesis, indomethacin and meclofenamate, on the renin release stimulated by isoproterenol and dibutyryl cAMP. We used an in vitro superfusion system of rat renal cortical slices. Neither indomethacin nor meclofenamate affected basal renin release. Isoproterenol (8 x 10(-7) M) increased renin and PGE2 release which was blocked by indomethacin (10(-4) M) and meclofenamate (10(-4) M). Dibutyryl cAMP stimulated renin release significantly, and this effect was not blocked by indomethacin (10(-4) M). Moreover, dibutyryl cAMP did not stimulate PGE2 release. In view of the fact that we have previously shown that PG-stimulated renin release is not blocked by propranolol and is enhanced by phosphodiesterase inhibitors, our present experiments suggest that the site of action of PGs on renin release is located between the beta-adrenergic receptor and the generation of cAMP.
...
PMID:The role of renal prostaglandins in the renin response to isoproterenol in the rat in vitro. 626 Apr 59

The regulation of cyclic AMP metabolism in the rat erythrocyte has been investigated during chronic exposure to the beta agonist isoproterenol. A triphasic response is observed: 1) an acute increase in cyclic AMP to levels four- to fivefold greater than basal, maximal by 1 minute (Phase I); 2) a gradual decline in cAMP content to levels near basal during the next 15-20 minutes (Phase II) and a second sustained rise in cAMP, maximal by 60 minutes, to a concentration greater than that observed during the first minute (Phase III). Extensively washed Phase II and Phase III cells are refractory to a second challenge by isoproterenol. In phosphodiesterase-inhibited intact Phase II and III cells adenylate cyclase activity is maximally activated. Isoproterenol has no effect on soluble phosphodiesterase activity but increases membrane-bound phosphodiesterase activity 3- and 2.2-fold in Phase II and Phase III cells, respectively. The activation of this membrane-bound enzyme activity appears to be mediated by the calcium-dependent regulatory protein, calmodulin, because 1) the amount of exogenous calmodulin required to achieve half-maximal activation of membrane-bound phosphodiesterase is 3.7, 2.0, and 1.2 micrograms in control, Phase III and Phase II membranes, respectively; and 2) there is less calmodulin in membrane-free lysates prepared from Phase II cells than control cells. These data support the idea that the major mechanism regulating cAMP content in the rat erythrocyte during chronic isoproterenol stimulation is the membrane-bound phosphodiesterase and that there is a translocation of calmodulin from the cytoplasm to the membrane during hormone stimulation.
...
PMID:Regulation of cyclic AMP metabolism in the rat erythrocyte during chronic beta-adrenergic stimulation. Evidence for calmodulin-mediated alteration of membrane-bound phosphodiesterase activity. 626 Sep 52

The hormonal control of cyclic nucleotide phosphodiesterase (EC 3.1.4.17) activity has been studied by using as a model the isoproterenol stimulation of cyclic AMP phosphodiesterase activity in C6 glioma cells. A 2-fold increase in cyclic AMP phosphodiesterase specific activity was observed in homogenates of isoproterenol-treated cells relative to control. This increase reached a maximum 3 h after addition of isoproterenol, was selective for cyclic AMP hydrolysis, was reproduced by incubation with 8-Br cycl AMP but not with 8-Br cyclic GMP and was limited to the soluble enzyme activity. The presence of 0.1 mM EGTA did not alter the magnitude of the increase in phosphodiesterase activity. Moreover, the calmodulin content in the cell extracts was not changed after isoproterenol. DEAE-Sephacel chromatography of the 100000 X g supernatant resolved two peaks of phosphodiesterase activity. The first peak hydrolyzed both cyclic nucleotides and was activated by Ca2+ an purified calmodulin. The second peak was specific for cyclic AMP but it was Ca2+- and calmodulin-insensitive. Isoproterenol selectively increased the specific activity of the second peak. Kinetic analysis of the cyclic AMP hydrolysis by the induced enzyme revealed a non-linear Hofstee plot with apparent Km values of 2-5 microM. Cyclic GMP was not hydrolyzed by this enzyme in the absence or presence of calmodulin and failed to affect the kinetics of the hydrolysis of cyclic AMP. Gel filtration chromatography of the induced DEAE-Sephacel peak resolved a single peak of enzyme activity with an apparent molecular weight of 54000.
...
PMID:Regulation by a beta-adrenergic receptor of a Ca2+-independent adenosine 3',5'-(cyclic)monophosphate phosphodiesterase in C6 glioma cells. 626 87

The purpose of this investigation was to examine the effects of beta-adrenergic and muscarinic cholinergic agonists on protein phosphorylation in intact frog atrium. beta-Adrenergic agonists increase and muscarinic agonists decrease 32P incorporation into a 165,000-dalton (165K) protein within less than 1 min. The concentrations of isoproterenol that produce increases in 32P incorporation into the 165K protein and in systolic tension are similar. Further, the changes in 32P incorporation and tension produced by isoproterenol occur with similar time courses. Carbamylcholine decreases tension somewhat more quickly and at lower concentrations than it decreases 32P incorporation, however. Isoproterenol-stimulated 32P incorporation is thought to be mediated by cAMP-dependent protein kinase because bath application of dibutyryl cAMP, cholera toxin, or phosphodiesterase inhibitors increase 32P incorporation into the 165K protein in intact atria. When heart homogenates are incubated in the presence of [gamma-32P]ATP, cAMP stimulates the incorporation of 32P into the 165K protein. cGMP is much less effective. We suggest that carbamylcholine decreases 32P incorporation into the 165K protein by a mechanism independent of cAMP levels because carbamylcholine inhibits the stimulation of 32P incorporation into the 165K band produced by 8-bromo cAMP in intact cells. Phosphorylation of the 165K protein occurs in cardiac muscle but not in other tissues. We hypothesize that the 165K protein is C-protein, because the 165K- and C-proteins have similar solubilities and are associated with the myofibril. Further, antibodies produced against the 165K protein bind to C-protein purified from rabbit heart and also bind to the same region of the myofibril where C-protein is found.
...
PMID:Effects of cholinergic and adrenergic agonists on phosphorylation of a 165,000-dalton myofibrillar protein in intact cardiac muscle. 627 7

Thirty-four vasodilators were screened in several in vitro biochemical assays related to smooth muscle excitation-contraction coupling, binding to beta 1-,beta 2-, and alpha-adrenergic receptors, inhibition of phosphodiesterase activity, and antagonism of calcium accumulation. Isoproterenol and perhexiline only exhibited binding to beta-adrenergic sites. Ergocryptine, tolazoline, and amotriphene only bound to alpha-adrenergic receptors. Leniquinsin, papaverine, proquazone, dioxyline, hoquizil, quazodine, and theophylline were active only as phosphodiesterase inhibitors. Isoxsuprine, nylidrin, and bencyclane bound to alpha- and beta-receptors. Pentoxifylline bound to beta 1-sites and inhibited phosphodiesterase. Cyclandelate bound to beta 2-sites and blocked calcium accumulation. Cinnarizine and flunarizine antagonized calcium accumulation and bound to alpha-sites. Prazosin bound to alpha-sites and inhibited phosphodiesterase. Ethaverine and dipyridamole were inhibitors of phosphodiesterase and calcium accumulation. Nafronyl bound to beta 2- and alpha-sites and antagonized calcium accumulation. Mebeverine bound to beta 2- and alpha-receptors and inhibited phosphodiesterase activity and calcium accumulation. Verapamil bound to alpha-sites, and blocked phosphodiesterase and calcium accumulation. Quinazosin bound to beta 2- and alpha-receptors and antagonized both phosphodiesterase activity and calcium accumulation. Vasodilators that were inactive in all assays included niacin, nicotinyl alcohol, inositol nicotinate, amyl nitrite, sodium nitroprusside, diazoxide, hydralazine, and protoveratrine. Vasodilators should not be considered as a single drug class since they act on various mechanisms related to coupling of neuronal excitation to muscular contractility.
...
PMID:Heterogeneity of biochemical actions among vasodilators. 627 30

The effects of bronchodilators and smooth muscle relaxants on mechanical responses and lung cyclic nucleotide levels in the isolated hemilung of Rana catesbeiana demonstrate striking differences in intensity and time course of drug action in an unstimulated preparation of airway smooth muscle. Isoproterenol, nitroprusside and nitroglycerin elicit a fast onset relaxation (minutes) with ceiling effects at 20, 22 and 43%, respectively, of maximal relaxation. Theophylline, dibutyryl cyclic AMP and papaverine produce maximal or near maximal relaxation, but require 8 to 32 hr for peak effect. Papaverine-induced relaxation is accompanied by a slow increase in lung cyclic AMP and cyclic GMP and is markedly accelerated by isoproterenol. Theophylline (10(-3) M) produces no change in cyclic nucleotide levels and its relaxant effect is not accelerated by isoproterenol. The hierarchy of relaxant responses suggests drug action at discrete loci in a highly compartmentalized effector chain, with cyclic AMP-dependent mechanisms separable into at least two components. The first is activated by isoproterenol and elicits a rapid, limited response, presumably reflecting an increase in cyclic AMP in a relatively restricted pool. The second is activated by papaverine and elicits a very slow, but complete relaxation, presumably reflecting a more pervasive or diffuse accumulation of cyclic AMP secondary to phosphodiesterase inhibition. The major portion of theophylline-induced relaxation in this preparation appears to be independent of changes in cyclic nucleotide metabolism.
...
PMID:Bronchodilator mechanisms in bullfrog lung: differences in response to isoproterenol, theophylline and papaverine. 629 Jun 38

1. The effects of isoprenaline (10(-6) M) on relaxation, unidirectional as well as net Ca(2+) fluxes, and cyclic AMP levels were investigated in rabbit aorta under the condition of high-K(+) depolarization in the presence of phentolamine (10(-5) M).2. Isoprenaline (10(-6) M) caused significant inhibition of Ca(2+) influx stimulated by 145 mM-K(+) (0 Na(+)) solution. The time courses of Ca(2+) influx inhibition and relaxation by isoprenaline were parallel. Isoprenaline also caused a significant inhibition of high-K(+)-induced gain in net Ca(2+) content.3. Ro 20-1724 (1 mM), a phosphodiesterase inhibitor, also caused relaxation and Ca(2+) influx inhibition in high-K(+)-depolarized rabbit aorta. Pre-treatment with Ro 20-1724 potentiated isoprenaline-induced Ca(2+) influx inhibition and relaxation.4. Isoprenaline and Ro 20-1724 each alone increased cyclic AMP levels. Furthermore pre-treatment with Ro 20-1724 caused potentiation of isoprenaline-induced increases in cyclic AMP levels.5. At submaximal concentration, D600 (10(-7) M) caused partial inhibition of high-K(+)-stimulated Ca(2+) influx and produced relaxation. However, unlike Ro 20-1724, it did not potentiate isoprenaline-induced Ca(2+) influx inhibition and relaxation. D600 does not increase cyclic AMP levels in smooth muscle.6. Dibutyryl cyclic AMP (1 mM), a lipid-soluble analogue of cyclic AMP, caused relaxation and inhibited high-K(+)-stimulated Ca(2+) influx.7. Isoprenaline failed to cause stimulation of Ca(2+) efflux in high-K(+)-depolarized rabbit aorta.8. It is concluded that the inhibition of Ca(2+) influx may be one of the mechanisms by which beta-receptor stimulation can reduce intracellular free Ca(2+) to promote relaxation of smooth muscle. The data support the involvement of cyclic AMP in this action of the beta-agonist.9. Since the experiments were conducted in 145 mM-K(+) (0 Na(+)) depolarizing conditions, the role of hyperpolarization or of a Na(+)-Ca(2+) exchange mechanism in isoprenaline-induced Ca(2+) influx inhibition and/or relaxation can be excluded.
...
PMID:Effects of beta-adrenergic stimulation on calcium movements in rabbit aortic smooth muscle: relationship with cyclic AMP. 629 69

Isoproterenol, dopamine, glucagon and dibutyryl cyclic AMP (DB-cAMP) increase renin release at low but not at control blood pressure. These findings suggest that autoregulated afferent arteriolar dilation is a prerequisite of renin release mediated by intracellular generation of cyclic AMP. To examine this hypothesis further the effects on renin release of theophylline, which would maintain high intracellular concentration of cAMP by inhibiting phosphodiesterase, were studied in anesthetized dogs. After inhibiting beta-adrenergic stimulation with propranolol, theophylline increased renin release significantly from 0.7 +/- 0.2 to 1.8 +/- 0.7 micrograms/min at control blood pressure and from 23 +/- 4 to 41 +/- 5 micrograms/min at a renal perfusion pressure of about 50 mmHg. The greater effect at low blood pressure occurred despite adjustment of the infusion rate of theophylline to keep arterial plasma concentration of theophylline unaltered. Isoproterenol infusion at low blood pressure raised renin release from 41 +/- 11 to 76 +/- 19 micrograms/min before and 54 +/- 13 to 108 +/- 31 micrograms/min during continuous infusion of theophylline. The renin release response to infusion of theophylline at low blood pressure was not enhanced by DB-cAMP infusion. We conclude that arteriolar dilation provides a condition for stimulation of renin release during the theophylline infusion. Theophylline infusion may augment the effect of isoproterenol on renin release by delaying the intracellular degradation of cAMP.
...
PMID:Conditions for augmentation of renin release by theophylline. 631 54


<< Previous 1 2 3 4 5 6 7 8 9 10

---